BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 26882436)

  • 1. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
    Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
    Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
    Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
    Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
    J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.
    Karnes HE; Duncavage EJ; Bernadt CT
    Cancer Cytopathol; 2014 Feb; 122(2):104-13. PubMed ID: 24227699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung.
    Stigt JA; 'tHart NA; Knol AJ; Uil SM; Groen HJ
    J Thorac Oncol; 2013 Aug; 8(8):1012-8. PubMed ID: 23807543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
    Sánchez-Font A; Chalela R; Martín-Ontiyuelo C; Albero-González R; Dalmases A; Longarón R; Alonso-Espinaco V; Curull V; Bellosillo B; Pijuan L
    Cancer Cytopathol; 2018 Oct; 126(10):860-871. PubMed ID: 30291816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas.
    Schneider F; Smith MA; Lane MC; Pantanowitz L; Dacic S; Ohori NP
    Am J Clin Pathol; 2015 Feb; 143(2):193-200; quiz 306. PubMed ID: 25596245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
    Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
    Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.
    Lewandowska MA; Jóźwicki W; Jochymski C; Kowalewski J
    Oncol Rep; 2013 Sep; 30(3):1045-52. PubMed ID: 23817662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
    Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
    Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
    Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non-small cell lung cancer specimens.
    Wu W; Huang Y; Guo J; Xie X; Li H; Cao Z; Wei H; Wu C
    Cancer Cytopathol; 2020 Aug; 128(8):545-552. PubMed ID: 32286726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
    Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
    Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.